Zevra Therapeutics wraps up acquisition of Acer Therapeutics
Zevra aims to advance in the development and commercialisation of treatments for rare diseases and support patient communities…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Nov 23
Zevra aims to advance in the development and commercialisation of treatments for rare diseases and support patient communities…
21 Nov 23
NeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS
20 Nov 23
Almirall will begin the commercial launch of the drug in Germany, with plans to progressively extend the rollout…
20 Nov 23
The approval was based on the positive results from ROSEWOOD Phase 2 study in which Brukinsa plus the…
20 Nov 23
The firm believes that the individuals using the Vitrakvi could consume the fungus and develop invasive blood fungal…
20 Nov 23
SMPaeds2 will investigate blood cancers and solid tumours in children and young people, including in the brain, muscle…
20 Nov 23
The approval and subsequent launch will enhance access to a critical treatment option for patients while serving to…
17 Nov 23
The approval was supported by interim analysis findings from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 study in…
17 Nov 23
DS-5670 is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain (RBD) of…
16 Nov 23
The primary focus of the combined entity's lead programmes will be on addressing presbyopia, the age-related decline in…